Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Myriad Genetics, Inc. (MYGN) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (1720)	11/16/2005 3:44:00 PM
From: tuck	Read Replies (2) \| Respond to of 2355

OK, according to the abstract, 207 patients were in the study, so that means 168 enrolled in the follow-on. We have an interesting finding of improved cognition, but the market doesn't seem at all impressed. We are missing some numbers, such as confidence intervals, p-values and the like. Not to mention how many patients were in the mild group in the follow-on portion of the study, and how many of those were on the high dose showing the effect. None of this is in the abstract, either. Makes me wonder how statistically significant those numbers given in the PR really are. Where's the beef? Cheers, Tuck